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tors from a sample of patients (or caregivers of pediatric
patients), physicians specialist in hemophilia care, pharmacists
with experience in storing/delivering coagulation factor concen-
trates. METHODS: A Discrete Choice Experiment was con-
ducted, by describing possible products with 7 attributes selected
from a previous pilot study: “viral safety”, “risk of anamnestic
response”, “possibility of undergoing major surgery”, “fre-
quency of infusions in prophylaxis”, “number of injections to
stop bleeding”, “time to stop bleeding”, “time to pain recovery”.
Cost, expressed as increase of health care taxes, was added to
estimate willingness to pay towards these attributes. The respon-
dents were asked to choose among 16 pair-wise choice sets.
A random-effect logit model was used to analyse the data.
RESULTS: Thirty-seven patients or proxies (their caregivers), 39
physicians, 25 pharmacists were interviewed. All the patients
had severe hemophilia A, historical median (min-max) peak
titre = 164 (5–16,400) BU/mL. Among all the respondents, the
hypothesized direction of preferences was conﬁrmed (e.g. lower
risk of infections was preferred than higher risk) and the impor-
tance of preferences was statistically signiﬁcant: p-values < 0.01
for every attribute. The 3 subgroups anyway reported different
preferences in some attributes. CONCLUSION: this study
revealed patients/caregivers’, physicians’ and pharmacists’ pref-
erences towards the products used to treat hemophilic patients
with inhibitors. Understanding the preferences from different
perspectives can be useful to optimize the beneﬁts deriving
from the decisions on treatments for hemophilic patients with
inhibitors.
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OBJECTIVES: Using a sample of adult Medicaid enrollees, this
study examined physician prescribing practices associated with
MDD. We compared behavioral, physical, and pharmacy service
use and cost outcomes associated with different prescribing pat-
terns. Speciﬁcally, we examined three cohorts of enrollees: 1)
persons with MDD; 2) persons with diabetic peripheral neuropa-
thy (DPN); and 3) persons with MDD and DPN. We compared
outcomes for patients prescribed Duloxetine to those prescribed
other antidepressant medications. METHODS: The sample
included 32,663 patients diagnosed with MDD and or DPN who
were enrolled in the Florida Medicaid Program during FY2003-
05. Three years of claims data were used to compare demograph-
ics, diagnostic characteristics, antidepressant medication use, and
service expenditures six months prior to and one year after the
index prescription event. RESULTS: Among persons diagnosed
with MDD, the majority (84.5%) received SSRIs alone or in
combination with other antidepressants, 29.2% received SNRIs
alone or in combination, and 15.3% received TCAs alone or in
combination. A large majority (86.5%) also received prescription
pain medication. Of these patients, more than half received pre-
scription narcotics on a daily basis. Predictors of increased
service use and cost following initiation of antidepressant treat-
ment included older age, female gender, and pre-index prescrip-
tion costs. Results indicated physical health care costs increased
after any switches in antidepressants. However, behavioral health
costs decreased for all treated patients over time, most dramati-
cally for inpatient service expenditures. Patients receiving Dulox-
etine reduced their narcotic use following treatment, while
patients receiving other antidepressant medications maintained
or increased narcotics use. CONCLUSION: Current data indi-
cates many patients with MDD also experience chronic pain
conditions requiring narcotics or other pain medications. SNRI’s
may facilitate a reduction in pain medication use and therefore
might be the antidepressant of choice for patients with co-morbid
MDD and chronic pain.
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OBJECTIVES: To summarize published data on the burden of
GAD to assist decision makers in Germany. METHODS: A
review of English-language studies on the human, health care and
economic burden of GAD in Germany. Studies were identiﬁed
using electronic databases (MEDLINE/EMBASE) and references
from published articles. RESULTS: National prevalence esti-
mates indicate that GAD affected 1.5% of adults in the general
population in the past 12-months and 5.3% of primary care
patients in the past 1-month. GAD commonly co-occurred with
other mental disorders, especially major depression (MD).
Impairments observed in people with GAD were not merely due
to comorbidity. People with pure GAD (GAD without comorbid
MD) reported high levels of occupational impairment that were
similar or greater in magnitude compared to that of people with
pure MD (MD without comorbid GAD). People with pure GAD
also reported more severe mental and physical health status
impairments compared to people with pure MD. High use of
health care resources among GAD primary care patients was
not solely due to comorbidity. The proportion of comorbid
GAD/MD cases was smaller than that of pure GAD cases
(4-week point prevalence estimates of 1.6% and 3.8%, respec-
tively). A greater proportion of primary care patients with
comorbid GAD/MD (43%) and pure GAD (42%) reported high
use of specialists (2 + visits/year) than pure MD patients (36%).
A greater proportion of GAD patients sought help for somatic
illness/complaints (48%), pain (35%) and sleep problems (33%)
than for anxiety (13%). GAD was considerably less likely to be
recognized and treated than MD. The per-patient cost of GAD
(€1628 in 2004) was higher than that of any other anxiety
disorder, owing to lost work and health care utilization. CON-
CLUSION: German data show that GAD is a distinct and bur-
densome disorder. Improved recognition and treatment of GAD
should be an important public health priority.
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OBJECTIVES: To present the outcomes associated with olanza-
pine treatment of schizophrenia patients participating in the
Olanzapine Post Marketing Surveillance in Japan (OPMS-J), and
to compare the maintenance rate of olanzapine in the OPMS-J
with that of typical and atypical antipsychotic medication in
the Schizophrenia Outpatient Health Outcomes (SOHO) study.
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METHODS: The OPMS-J is 12-month, prospective, observa-
tional study of the health outcomes associated with olanzapine
treatment in Japan. Patient enrollment started before November
2003, and completed by July 2004. A total of 1955 out/in-
patients were enrolled in the OPMS-J, of whom 1849 were
considered as qualiﬁed subjects for the analysis of effectiveness.
Four types of outcomes were measured in the study: social activ-
ity (social activity was assessed using single-item questions that
asked whether the patient was involved in any social interactions
in the previous 4 weeks), EQ-5D, Clinical Global Impression-
Schizophrenia scale (CGI-SCH) and the maintenance rate of
olanzapine. Regarding the maintenance rate of olanzapine, the
OPMS-J was compared with the SOHO study, as an external
control, with typical and atypical antipsychotic medication
including olanzapine. RESULTS: The three outcomes, i.e., social
activity, EQ-5D and the CGI-SCH, all, signiﬁcantly improved
when the scores at the baseline were statistically compared with
those at the endpoint of 12-month follow-up or the end of the
surveillance (p < 0.001). Also, the deterioration rate of patients
status was observed as less than 5% in the group measured with
the CGI-SCH. The maintenance rate of olanzapine in the
OPMS-J was 68.25% (n = 1262) in the 12-month follow-up
duration, which is similar to that of SOHO study reported at the
12-month endpoint, ranging from 79.5% to 51.4%. CONCLU-
SION: The improvement of patient-reported outcomes with
respect to olanzapine was conﬁrmed in the OPMS-J, a post
marketing surveillance in Japan. Also, the maintenance rate of
olanzapine in Japan was similar as that in the European study.
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OBJECTIVES: To compare the efﬁcacy of antipsychotics in the
treatment of negative symptoms of schizophrenia. METHODS:
Studies were identiﬁed by searching for randomized, double-
blind, placebo-controlled trials reporting data on efﬁcacy of
antipsychotics on negative symptoms in schizophrenia. A struc-
tured literature review was conducted in the following databases:
Pubmed, The Cochrane Central Register of Controlled Trials
(CENTRAL), Proquest Health and Medical Complete, Science
Citation Index Expanded, and Current Contents Connect. The
outcome measure was the mean change in negative symptoms
score from baseline to end-point on the PANSS-N, SANS, and
BPRS retardation factor (BPRS-R) scales. As we obtained data
from different assessment instruments to be combined, we chose
a standardized statistic—Cohen’s d—which is a type of standard-
ized mean difference. The Der-Simonian and Laird random
effects model was used to synthesize data. All calculations were
made using STATA 8.2, with 95% conﬁdence intervals and sig-
niﬁcance level of 0.05. RESULTS: A total of 46 homogeneous
trials (Q = 45.18, df = 50, p = 0.667, I2 = 0%) were included;
4 with amisulpride, 3 with ziprasidone, 9 with olanzapine, 8
with risperidone, 11 with quetiapine, 8 with haloperidol, 2 with
zotepine, and 1 with chlorpromazine. Ranked effect sizes
(Cohen’s d) favoring active treatment against placebo were for
amisulpride; 0.52 (p < 0.001), ziprasidone; 0.50 (p < 0.001),
olanzapine; 0.43 (p < 0.001), risperidone; 0.40 (p < 0.001), que-
tiapine; 0.36 (p < 0.001), haloperidol; 0.34 (p < 0.001), zotepine;
0.31 (p = 0.11), and chlorpromazine; 0.12 (p = 0.532). CON-
CLUSION: The efﬁcacy of antipsychotics on negative symptoms
seems to be drug-dependent. Amisulpride and ziprasidone
showed better overall effects than the other antipsychotics.
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OBJECTIVES: To review systematically the comparative efﬁcacy
of second-generation antidepressants for the treatment of acute
phase major depressive disorder (MDD) in adults. METHODS:
To identify relevant articles we searched MEDLINE®, Embase,
The Cochrane Library, and the International Pharmaceutical
Abstracts from 1980 to 2006 (February). We included double-
blinded, randomized controlled trials (RCTs) of good or fair
internal validity. If data were sufﬁcient, we conducted relative
beneﬁt and effect size meta-analyses to assess the comparative
efﬁcacy of two drugs. If not enough data were available for
meta-analyses, we conducted adjusted indirect comparisons
based on placebo controlled RCTs. For adjusted indirect com-
parisons we employed meta-regression and network meta-
analysis as statistical methods. RESULTS: Overall we included
108 studies. Data was sufﬁcient to conduct meta-analyses on four
comparisons. For the other 62 possible comparisons we con-
ducted adjusted indirect comparisons. Outcomes of interest were
relative beneﬁt (RB) of response. We found statistically signiﬁ-
cant differences in response rates favoring escitalopram over
citalopram (RB: 1.19; 95% CI, 1.08–1.30), sertraline over ﬂu-
oxetine (RB: 1.11; 95% CI, 1.01–1.25), and venlafaxine over
ﬂuoxetine (RB: 1.12; 95% CI, 1.00–1.25). However, these dif-
ferences are modest and likely not clinically signiﬁcant. Adjusted
indirect comparisons did not indicate differences in efﬁcacy
among second-generation antidepressants. In other ﬁndings, mir-
tazapine had a faster onset of action, bupropion led to improved
sexual functioning, and nefazodone and trazodone to improved
sleep quality than comparator drugs. No differences in effective-
ness, adherence, or efﬁcacy in subgroups could be detected.
CONCLUSION: Our ﬁndings indicate that the current evidence
does not warrant the choice of one second-generation antidepres-
sant over another based on differences in efﬁcacy and effective-
ness. However, other differences with respect to onset of action
and some aspects of quality of life may be relevant for the choice
of a medication.
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OBJECTIVES: To analyse and compare the remission rates
reported for various doses of duloxetine (DXT) in the pivotal
RCTs conducted in major depression (MD). METHODS:
Number of remitters (intention-to-treat approach) and number
of patients randomised to the different treatment arms were
obtained from the Lilly webpage (www.lillytrials.com/results/
by_product/results_cymbalta.html). Data from 6 RCTs including
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